Leading the Way in Life Science Technologies

GEN Exclusives

More »

Point of View

More »
Aug 1, 2010 (Vol. 30, No. 14)

Justifying Regulation of DTC Tests

Good Policies Are in the Best Interests of Direct-to-Consumer Companies and Consumers

  • Goals of Consumer Regulation

    So what are the goals of consumer regulation? The simplest reason behind some kinds of regulations is to increase efficiency by standardizing things like weights and measures and various technical protocols that make it easier for business to be conducted. Here, government plays a simple yet important coordinative function. But, perhaps, the most obvious reason for regulations in at least some domains is consumer protection.

    Some regulations seek to protect consumers by means of outright prohibitions, such as the prohibition on retail sales of heroin. Other regulations protect consumers by requiring businesses to provide prospective customers with information. Among information-based protection regulations, we can further distinguish two forms: regulations that require making sure consumers are informed of dangers (e.g., the dangers of cigarettes) and regulations that require giving consumers the information to makes sure that products meet their particular needs (e.g., the need for particular nutritional characteristics in foods).

    Sometimes, of course, regulations lack good justification. Regulations are made by humans and are hence subject to the full range of human flaws. But it’s important to see—and differentiate among—the various ethical justifications that make sense of various regulations in the first place.

  • "It's Only Information"

    Finally, a word about regulating information-based services. Some have expressed shock at the idea that government might want to regulate a service like genetic testing, a service that, after all, merely provides information. Of course, the idea that test results are “merely information” is far from reassuring.

    Information can obviously be dangerous in many ways. This is not to say that the kind of information produced by a whole-genome scan is particularly dangerous; it’s just a reminder that information-based services are not inherently risk-free.

    In part, the worry here is related to the difference between data and information. After all, the reason that the results of tests by a company like Navigenics or 23andMe are worth paying for is that those companies don’t just give customers a series of C’s, G’s, A’s and T’s. They also provide some level of interpretation. And such interpretation is an inherently normative process—a process of deciding how to interpret the data, and which information, at which level of complexity, ought to be delivered to the paying customer. There really is nothing “mere” about information in a context like this.

    Another perspective from which to criticize regulation of DTC genetic tests points out that such regulations erect barriers to individuals gaining information that is, after all, about them. How can government deny me information about myself? But it’s critical to see that denying a company the unfettered right to sell something is importantly different from denying consumers the right to buy it. It’s also important to see that sometimes we put regulations in place not to because every consumer needs protection but because some do. Not all such regulations are justifiable; but surely at least some are, and the debate needs to be conducted in recognition of that fact.

  • Conclusion

    None of this implies that companies wishing to sell genetic testing services directly to consumers ought to be whole-hearted fans of maximal government regulation. There’s room for honest disagreement about the usefulness of various tests and about the possibility that consumers will be harmed or even just misled by them. But it’s pretty widely understood that having good, clear regulations can, in fact, be in the interests of business.

    Clear regulations, after all, provide a stable environment in which to invest and may well provide a measure of safety from ad hoc administrative rebuke (by agencies like the FDA or the Federal Trade Commission) or even from plaintiffs’ attorneys. But my larger point here is that companies in the DTC genetic testing field need to formulate their responses to the question of regulation in a way that demonstrates a sensitivity to the legitimate goals of regulation. For the goals of regulation are, at heart, the goals of the free market itself: to foster exchanges of goods and services that truly do end up making life better for us all.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »